Ardelyx
Oct 23, 2023
Ardelyx Overcomes Hurdles to Secure FDA Approval for Xphozah in Chronic Kidney Disease Treatment
Ardelyx has struck gold on its third attempt with Xphozah (tenapanor), the chronic kidney disease medication. Following two prior rejections, the FDA has granted its long-awaited approval. Xphozah, an innovative phosphate absorption inhibitor, is now officially sanctioned for the management of serum phosphate level...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
